Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared on X:
“Two phase III BCMA bispecific trials – two strengths:
- Efficacy edge: teclistamab (PFS HR 0.29 vs 0.40)
- Safety/convenience edge: etentamig – monthly dosing; single-SUD CRS 28.3% (no G3) and ICANS 0.9%.
I think the CRS/ICANS incidence will make Etentamig an easy pick for community oncologists!”
Other articles about multiple myeloma on OncoDaily.
